Effect of interleukin 23 inhibitors (risankizumab and guselkumab) on cardiovascular and cerebrovascular risk in psoriasis patients
- 2 October 2025
- journal article
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 44 (4) , 544-550
Abstract
Psoriasis is a chronic systemic inflammatory disease mediated by the immune system. Interleukin-23 (IL-23) plays a key role in its pathogenesis by amplifying inflammation, triggering atherogenic dyslipidemia and insulin resistance, and thereby increasing cardiovascular and cerebrovascular risk. This study aimed to evaluate the effect of the IL-23 inhibitors risankizumab and guselkumab, used in psoriasis treatment, on cardiovascular and cerebrovascular risk through the plasma atherogenic index (PAI) and triglyceride-glucose (TyG) index. This retrospective study included 110 patients diagnosed with psoriasis and treated with risankizumab (n = 61) or guselkumab (n = 49). Psoriasis Area and Severity Index (PASI) scores, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C) levels and fasting blood glucose (FBG) values at baseline and at 6 months of treatment were obtained from patient records. The plasma atherogenic index (PAI) was calculated as log₁。(TG/HDL-C), and the triglyceride-glucose (TyG) index as log₁。(TG × FBG / 2). In both IL-23 inhibitor groups included in the study, PASI scores, PAI, and TyG index values showed a significant decrease from baseline at the 6th month of treatment (p < 0.05). However, there was no significant difference in the reduction of index levels between the groups (p > 0.05). IL-23 inhibitors can reduce atherogenic dyslipidemia and insulin resistance alongside dermatological improvement in the treatment of psoriasis. This suggests a potential role for these agents in reducing the risk of cardiovascular and cerebrovascular disease. However, large-scale, long-term studies are needed to confirm these beneficial effects.Keywords
This publication has 30 references indexed in Scilit:
- Associations between the atherogenic index of plasma and psoriasis among US adults: A cross-sectional study based on NHANES 2009 to 2014Medicine, 2024
- Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective studyArchives of Dermatological Research, 2024
- Etiopathogenesis of Psoriasis: Integration of Proposed TheoriesImmunological Investigations, 2024
- PsoriasisThe Lancet, 2021
- Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular IllnessesArchives of Medical Research, 2019
- Importance of T Lymphocytes in Brain Injury, Immunodeficiency, and Recovery after Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2012
- Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerabilityBasic Research in Cardiology, 2010
- Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid ConditionsJournal of Investigative Dermatology, 2010
- PsoriasisNew England Journal of Medicine, 2009
- Association of Psoriasis With Coronary Artery, Cerebrovascular, and Peripheral Vascular Diseases and MortalityArchives of Dermatology, 2009